June 15, 2020 / 11:06 AM / 20 days ago

BRIEF-Lilly Begins Phase 3 Clinical Trial With Baricitinib For Hospitalized COVID-19 Patients

June 15 (Reuters) - Eli Lilly and Co:

* LILLY BEGINS A PHASE 3 CLINICAL TRIAL WITH BARICITINIB FOR HOSPITALIZED COVID-19 PATIENTS

* ELI LILLY AND CO - DATA WILL COMPLEMENT ONGOING NIAID TRIAL AND INVESTIGATOR-INITIATED TRIALS

* ELI LILLY AND CO - STUDY WILL FURTHER UNDERSTANDING OF BARICITINIB’S POTENTIAL AS A COVID-19 TREATMENT

* ELI LILLY AND CO - LILLY EXPECTS TO ENROLL 400 PATIENTS IN TRIAL, WITH DATA EXPECTED IN NEXT FEW MONTHS

* ELI LILLY AND CO - PATIENTS WILL RECEIVE BARICITINIB OR PLACEBO FOR UP TO 14 DAYS OR UNTIL DISCHARGE FROM HOSPITAL

* ELI LILLY - SUPPORTING SELECT ONGOING MULTISITE, SINGLE-SITE INVESTIGATOR-INITIATED TRIALS IN EUROPE & NORTH AMERICA FOR PATIENTS WITH COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below